Search Results
Viewing: 451-460 of 566 | All
News
FDA Approves First Gene Therapy Treatment for SMA Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its approval of Zolgensma® for spinal muscular atrophy (SMA) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.
Career Expo
Join us for our first annual Career Expo on Friday, January 20. Explore our available career opportunities, connect with recruiters and managers, and discover why you will love working at Nationwide Children's.
Article
Publications and Presentations
Condition
Intracranial Hypertension (Pseudotumor Cerebri)
Idiopathic intracranial hypertension, sometimes called pseudotumor cerebri, is a condition in which the cerebro-spinal fluid is not able to drain normally.
Article
Rehab Outcomes
Our approach to inpatient rehabilitation focuses on the path ahead. Read about our demonstrated differences and outcomes.
Article
Our Mission and Strategic Plan
The Abigail Wexner Research Institute at Nationwide Children's Hospital is dedicated to enhancing the health of children by engaging in high-quality, cutting-edge research according to the highest scientific and ethical standards.
Article
Stottmann Lab
The long-term goals of the Stottmann Lab are to understand the genes and molecular mechanisms guiding normal development of both the brain and face.
Article
Wedemeyer Lab
The Wedemeyer Laboratory seeks to apply state of the art genomics technologies to better understand common neurosurgical disease processes in children and improve the overall neurosurgical care for the children in our community.
Article
Psychosocial Services
When a child is born with a cleft lip and/or palate or any craniofacial condition, the emotional health and well-being of the child and family are just as important as the child’s medical care.
Article
Moscato Lab
The Moscato Lab, led by Emily Moscato, PhD, focuses on designing, testing and implementing equitable behavioral interventions to improve quality of life and neurodevelopmental trajectories for young children with chronic conditions impacting the central nervous system.